Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
$0.63
-7.4%
$4.97
$0.24
$1.49
$9.37M2.82127,174 shs176,619 shs
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
$0.60
$0.59
$0.59
$0.60
$31.81M-0.151 shsN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$9.36
$9.36
$9.10
$12.00
$167.08M0.53600 shsN/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
$54.99
$54.93
$14.91
$55.19
$1.34B0.03931,731 shsN/A
Savara Inc. stock logo
SVRA
Savara
$2.28
+3.2%
$2.68
$1.89
$5.11
$381.97M0.321.28 million shs2.77 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
0.00%-6.82%-7.65%-60.00%-86.98%
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
0.00%0.00%0.00%+31.90%+335.73%
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00%0.00%0.00%0.00%-22.00%
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
0.00%0.00%0.00%0.00%0.00%
Savara Inc. stock logo
SVRA
Savara
0.00%+7.28%-3.49%-20.22%-45.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
2.5688 of 5 stars
3.31.00.00.02.83.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
0.00
N/AN/AN/A
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
0.00
N/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00
N/AN/AN/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
0.00
N/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
2.60
Moderate Buy$5.60145.61% Upside

Current Analyst Ratings Breakdown

Latest NWPHF, SRRA, GEMP, HBPCF, and SVRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Savara Inc. stock logo
SVRA
Savara
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$6.00 ➝ $2.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$3.00 ➝ $2.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $8.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/A$0.54 per shareN/A
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/AN/AN/AN/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$6.82M24.50N/AN/A$0.21 per share44.57
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
$300K4,476.00N/AN/A$6.16 per share8.93
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/A$1.00 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
-$23.64MN/A0.00N/AN/A-419.70%-173.05%N/A
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
-$6.82M-$0.14N/AN/AN/AN/A-694.39%N/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
-$17.63MN/A0.00N/AN/AN/AN/AN/AN/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
-$94.66M-$6.77N/AN/AN/AN/A-111.88%-100.01%N/A
Savara Inc. stock logo
SVRA
Savara
-$95.88M-$0.48N/AN/AN/AN/A-65.88%-52.35%8/11/2025 (Estimated)

Latest NWPHF, SRRA, GEMP, HBPCF, and SVRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/16/2025Q3 2025
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/A-$0.02N/A-$0.02N/AN/A
5/13/2025Q1 2025
Savara Inc. stock logo
SVRA
Savara
-$0.12-$0.12N/A-$0.12N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/AN/A
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/AN/AN/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/AN/AN/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
N/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/A
0.67
0.67
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/A
0.99
0.99
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
0.02
21.27
21.27
Savara Inc. stock logo
SVRA
Savara
0.20
14.91
14.91

Institutional Ownership

CompanyInstitutional Ownership
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
17.53%
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
99.30%
Savara Inc. stock logo
SVRA
Savara
87.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
914.87 millionN/ANot Optionable
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
953.02 million48.99 millionNot Optionable
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
2217.85 millionN/ANot Optionable
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
10924.42 million13.65 millionOptionable
Savara Inc. stock logo
SVRA
Savara
N/A172.84 million163.97 millionOptionable

Recent News About These Companies

Savara Independent Director Acquires 177% More Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gemphire Therapeutics stock logo

Gemphire Therapeutics NASDAQ:GEMP

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.

Helix Biopharma stock logo

Helix Biopharma OTCMKTS:HBPCF

$0.60 0.00 (0.00%)
As of 06/27/2025

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Newron Pharmaceuticals stock logo

Newron Pharmaceuticals OTCMKTS:NWPHF

$9.36 0.00 (0.00%)
As of 06/27/2025

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

Sierra Oncology stock logo

Sierra Oncology NASDAQ:SRRA

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.

Savara stock logo

Savara NASDAQ:SVRA

$2.28 +0.07 (+3.17%)
As of 04:00 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.